While different BCR::ABL1 tyrosine kinase inhibitors (TKIs) have strongly improved the overall survival of most CML patients, TKI-resistance and -intolerance result in disease recurrence and prevent cure35,36. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.